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Abstract 
Background: Early diagnosis of familial transthyretin (TTR) amyloid diseases remains challenging 
because of variable disease penetrance. Currently, patients must have an amyloid positive tissue 
biopsy to be eligible for disease-modifying therapies. Endomyocardial biopsies are typically amyloid 
positive when cardiomyopathy is suspected, but this disease manifestation is generally diagnosed 
late.  Early diagnosis is often difficult because patients exhibit apparent symptoms of 
polyneuropathy, but have a negative amyloid biopsy. Thus, there is a pressing need for an additional 
early diagnostic strategy for TTR-aggregation-associated polyneuropathy and cardiomyopathy.  
Methods and Findings: Global peripheral blood cell mRNA expression profiles from 263 
tafamidis-treated and untreated V30M Familiar Amyloid Neuropathy patients, asymptomatic V30M 
carriers, and healthy, age- and sex-matched controls without TTR mutations were used to 
differentiate symptomatic from asymptomatic patients. We demonstrate that blood cell gene 
expression patterns reveal sex-independent, as well as male- and female-specific inflammatory 
signatures in symptomatic FAP patients, but not in asymptomatic carriers. These signatures 
differentiated symptomatic patients from asymptomatic V30M carriers with >80% accuracy. There 
was a global downregulation of the eIF2 pathway and its associated genes in all symptomatic FAP 
patients. We also demonstrated that the molecular scores based on these signatures significantly 
trended toward normalized values in an independent cohort of 46 FAP patients after only 3 
months of tafamidis treatment.  
Conclusions: This study identifies novel molecular signatures that differentiate symptomatic FAP 
patients from asymptomatic V30M carriers as well as affected males and females. We envision 
using this approach, initially in parallel with amyloid biopsies, to identify individuals who are 
asymptomatic gene carriers that may convert to FAP patients. Upon further validation, peripheral 
blood cell mRNA expression profiling could become an independent early diagnostic. This 
quantitative gene expression signature for symptomatic FAP could also become a biomarker to 
demonstrate significant disease-modifying effects of drugs and drug candidates. For example, when 
new disease modifiers are being evaluated in a FAP clinical trial, such surrogate biomarkers have 
the potential to provide an objective, quantitative and mechanistic molecular diagnostic of disease 
response to therapy. 
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Introduction 
One of more than 100 mutations in the plasma 
protein transthyretin (TTR) destabilizes it, enabling 
aggregation, which appears to cause the amyloid 
disease familial amyloid polyneuropathy (FAP) [1, 2]. 
FAP is an autosomal dominant long fiber 
sensory-motor and autonomic neuropathy, often 
accompanied by cardiomyopathy [3]. The most 
common FAP-associated mutation is V30M. FAP is 
usually fatal 10 to 15 years after onset of symptoms if 
untreated [4-7]. 
The tetrameric TTR protein is secreted largely by 
the liver [8]. In heterozygotic FAP patients, the 
tetramers are composed of mutant and/or wild-type 
(WT) TTR subunits in the statistically predicted 
stoichiometries. Rate-limiting tetramer dissociation, 
followed by partial TTR monomer denaturation, 
facilitates concentration-dependent aggregation of 
predominantly mutant TTR [9, 10]. There is strong 
genetic and pharmacologic evidence that extracellular 
TTR aggregation causes degeneration in tissues not 
synthesizing TTR, including the peripheral and 
autonomic nervous systems, through cell 
non-autonomous mechanisms that are still not well 
understood [9, 11-15]. 
Liver transplantation from a donor with two 
normal TTR genes replaces the mutant allele in FAP 
heterozygotes [8, 14, 16, 17]. This surgical form of 
gene therapy has been performed on > 2000 patients, 
slowing FAP progression and extending lifespan [16, 
18, 19]. Clinical trial results demonstrate that 
tafamidis and diflunisal are also effective for the 
amelioration of FAP [20-22]. These TTR kinetic 
stabilizers bind to the unoccupied thyroxine binding 
sites within TTR tetramers, dramatically slowing 
tetramer dissociation and inhibiting TTR aggregation 
[23, 24].  
The amyloid hypothesis posits that TTR 
aggregation causes amyloidosis. Though the genetic 
and pharmacologic evidence is convincing [20-22, 25, 
26], we still do not understand the variable clinical 
penetrance of these diseases. We envision that there 
are additional triggers or modifiers of the onset and 
rate of progression of FAP. For clinicians, it remains 
difficult to identify those TTR mutation carriers who 
are at highest risk for developing symptomatic FAP. 
A facile method for monitoring TTR mutation carriers 
who convert from being asymptomatic to 
symptomatic is important because there is evidence 
that earlier treatment results in better outcomes [8, 
17-22].  
A definitive diagnosis of symptomatic FAP 
requires the presence of TTR amyloid via biopsy, 
which can be challenging to detect as amyloid 
deposition is not uniform [27] [29]. There are currently 
no accepted early diagnostic approaches that can be 
used in parallel with amyloid biopsies to identify 
carriers who have transitioned to FAP patients. A 
minimally invasive (i.e., blood) molecular diagnostic 
for the sensitive and early detection of symptomatic 
FAP in individuals at risk is the first envisioned 
application of our peripheral blood cell 
transcriptional signature approach. A potential 
second use would be in symptomatic patients, 
wherein a quantitative molecular signature could 
reflect both the burden of disease (upon correlation 
with clinical symptoms) and the response of each FAP 
patient to therapy through normalization of the 
signature. The latter could be especially useful for 
determining the minimal effective dosage of currently 
available drugs, and for use as a surrogate biomarker 
in clinical trials evaluating novel agents [20-22].  
Herein, we tested three hypotheses: 1) that 
peripheral blood cell gene expression profiling of 
symptomatic FAP patients vs. asymptomatic carriers 
would reveal genomic signatures reflective of clinical 
status, 2) that tafamidis treatment would normalize 
these signatures, and 3) that genes exhibiting 
transcriptional changes in blood can be mapped to 
functional pathways that may provide further 
mechanistic insights into FAP etiology. This study 
was made possible by the availability of blood 
samples from clinically well characterized FAP 
patients being cared for by experienced clinicians at 
the Hospital de Santo António, Porto, Portugal. The 
FAP patients all carry the same autosomal dominant 
V30M mutation, whose prevalence in that population 
is estimated to be 1/1000 [30]. The response to therapy 
component of this study was enabled because 
tafamidis was approved for use by the European 
Medicines Agency in November 2011 and in Portugal 
shortly thereafter [21].  
Given that male V30M FAP patients have earlier 
onset and more aggressive disease progression than 
female subjects with the same mutation, we also 
asked if there were any gender-specific features of the 
disease that might be revealed by these transcriptional 
signatures. It could be that males would benefit from 
a higher dose of tafamidis relative to females, and 
individuals with highly destabilizing mutations 
would also benefit from a higher dose of tafamidis. 
Materials and Methods 
Study Subjects: Tafamidis-treated and 
untreated V30M FAP patients, asymptomatic V30M 
carriers, and healthy, age- and sex-matched controls 
without TTR mutations provided informed consent at 
the Hospital de Santo António, Porto, Portugal. Whole 
blood (5 ml) was collected in PAXgene tubes (Qiagen) 
from a total of 309 human subjects. The study 
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comprised 7 subject groups: Normal Male Controls 
(n=37); Normal Female Controls (n=43); Symptomatic 
Males with V30M FAP (n=46); Symptomatic Females 
with V30M FAP (n=50); Asymptomatic Males 
carrying the V30M mutation linked to FAP (n=41); 
and Asymptomatic Females carrying the V30M 
mutation linked to FAP (n=46). These 6 subject 
groups, representing 263 total expression arrays, were 
randomized into two independent cohorts with 
roughly similar proportions of each subject group: 
Discovery (n=150) and Validation (n=113). In 
addition, tafamadis-treated patients (n=46; males = 
23, females = 23) were analyzed as a single validation 
cohort for studying response to therapy.  
RNA Extraction and Microarray Processing: 
RNA was extracted from whole blood with the 
PAXgene RNA Whole Blood Kit. Each RNA sample 
(100 ng) was amplified and labeled with the Ambion 
WT Express Kit and hybridized to Affymetrix 
HuGene 1.1 ST Arrays using the Affymetrix 
GeneTitan Multi-Channel (MC) platform. Normalized 
signals were generated using Robust Multichip 
Average (RMA) in Partek Genomics Suite software 
version 6.6. Probesets on the DNA microarrays with 
low expressed signals were determined using a kernel 
density plot and signals <Log2 of 6 were excluded 
from analysis.  
Microarray Analysis: We performed statistical 
power and sample size calculations for the microarray 
profiling of whole blood using the sample size 
estimation tool implemented in Partek genomics Suite 
[31, 32].  To detect a low fold-change of 1.3-fold at a 
p-value <0.005 that we would accept for a biological 
signal or biomarker gene at a power of 85%, a sample 
size of 45 samples per group for whole blood is 
necessary. Therefore, we were more than adequately 
powered even for the Discovery cohort used in this 
study. None of the samples were excluded based on 
the standard Affymetrix Quality Control metrics and 
by Principal Components Analysis plots derived in 
Partek Genomics Suite. Class comparisons were 
performed using a 1-way ANOVA model using the 
Method of Moments [33]. The one-way ANOVA that 
we employed to detect differentially expressed genes 
is also robust and tolerates reasonable levels of 
experimental data variance. Moreover, the danger of 
violating the normal distributions corresponds with 
the possibility to detect false positives, which we have 
controlled for with a stringent False Discovery Rate 
(FDR) of <5%. Class predictions were performed with 
the Support Vector Machines (SVM) algorithm. To 
correct for the possibility of over-fitting of the 
predictors, we used the bootstrapping method of 
Harrell et al. where the original data set is sampled 
500 times with replacement and the Area Under the 
Curves (AUCs) calculated for each resampling or 
bootstrap iteration [34, 35]. Receiver Operating 
Characteristic (ROC) curves were generated using 
pROC in R [36]. ROC curves were plotted using the 
posterior probabilities of a sample being called 
symptomatic or not based on SVM or Logistic 
Regression models. Diagnostic metrics were 
calculated based on the number of true and false 
positives using the formulae given below: Sensitivity 
= (TP/(TP+FN)), Specificity = (TN/(FP+TN)), 
Positive Predictive Value = (TP/(TP+FP)) and 
Negative Predictive Value = (TN/(FN+TN)). The 
STARD flowchart describing study design and 
diagnostic marker pipeline is shown in Additional file 
1: Supplemental Methods. We developed molecular 
scores based on gene expression signals for the 
highest value predictive signatures. Details about the 
development of the molecular scores are given in 
Additional file 1: Supplemental Methods. 
Scores were tested for differences using the 
two-sample t-test for different subjects in each group. 
The two groups are assumed to be normally 
distributed and have equal variance (for the equal 
variance t-test). Significant differential gene 
expression for each of the different group 
comparisons were mapped to functionally significant 
biological pathways using Ingenuity Pathways 
Analysis (Qiagen). Clinical study parameters were 
tested using paired t-test for continuous variables and 
McNemar’s chi-square test for categorical variables, 
including prevalence. CEL files and normalized signal 
intensities are posted at the NIH Gene Expression 
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo; 
accession number GSE 67784). 
Plasma Proteomic Analysis: A multi-analyte 
panel of 45 Luminex bead assays (Human 
InflammationMAP v1.0; Myriad/Rules Based 
Medicine, Austin, TX) was used to profile a selected 
subset of 40 plasma samples to validate the 
pro-inflammatory state indicated by analysis of the 
microarray data. These comprised 10 samples each 
from the four studied groups of patients with FAP 
mutations: symptomatic vs. asymptomatic, males vs. 
females.  
Results 
Patient Characteristics 
All of our plasma samples, including those from 
genetically similar and locally-collected healthy 
controls, asymptomatic V30M carriers, symptomatic 
V30M FAP patients, and tafamidis-treated patients 
were collected from one location, Hospital de Santo 
António in Porto, Portugal. Patients were classified as 
symptomatic if they had symptoms and an irregular 
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physical exam as well as abnormal laboratory exams 
that confirmed cardiac and/or neuropathic 
involvement. The severity of peripheral nerve and 
cardiac involvement is defined in the legend to Table 
1. The demographics for the discovery and validation 
cohorts are provided (Table 1, controls and patients; 
Table 2, asymptomatic vs. symptomatic patients). 
Controls for the Discovery and Validation sets (n=46 
and 34, respectively) were local Portuguese, healthy, 
age- and sex-matched subjects. Symptomatic patients 
were significantly older than asymptomatic patients, 
had higher white blood cell counts and had 
significantly increased levels of proteinuria despite 
normal creatinine levels. Symptomatic alkaline 
phosphatase levels were higher but not those of 
aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT). Although we acknowledge 
that measures of high-sensitivity C-reactive protein 
(hsCRP) are often employed in inflammation studies, 
we did not assess hsCRP levels since our 
inflammation findings emerged during analysis and 
long after the clinical samples had been collected in 
Portugal. Symptomatic patients had significant 
clinical peripheral nerve and cardiac involvement. 
The degree of neuropathic involvement was assessed 
using the Neuropathy Impairment Score-Lower 
Limbs (NIS-LL) and the Norfolk Quality of Life 
Diabetic Neuropathy Total Score (TQOL). The 
presence of cardiomyopathy was assessed by 
echocardiography, electrocardiography and 
measurement of B-type Natriuretic Peptide (BNP) to 
gauge congestive heart failure. The treated patients 
profiled in this study had received 3 months of 
commercially available and self-administered 
tafamidis therapy (20 mg once daily) at the time of 
blood sampling [22]. Among the symptomatic FAP 
patients 29/96 (30%) were on neuropathy medication 
(predominantly pregabalin or gabapentin) and none 
in the asymptomatic group were on these 
medications. However, there was no significant 
differential expression of genes among our classifier 
molecular signatures based on the medications as 
determined by ANOVA and supervised hierarchical 
clustering (Supplemental Methods). 
 
Table 1.  Patient and control Discovery and Validation set Demographics* 
Characteristic Discovery Set (n = 150) Validation Set (n = 113) 
 Control (n=46) Patient (n=104) Control (n=34) Patient (n=79)  
Sex—Female (n (%)) 25 (54.4) 55 (52.9) 18 (52.9) 41 (51.9) 
Age (years) (mean(SD)) 39.4 (11.4) 40.4 (14.3) 39.1 (15.0) 38.3 (12.6) 
BMI (kg/m2) (mean(SD))  24.5 (5.0)  24.4 (4.8) 
  (n=95)  (n=75) 
Parental Inheritance (n (%))     
 Mother  47  (45.2)  41  (51.9) 
 Father  48  (46.2)  33  (41.8) 
 Both  1    (1.0)  5    (6.3) 
 Unknown  8    (7.7)   
WBC (mean (SD))  7.1 (1.9)  7.2 (1.9) 
  (n=97)  (n=76) 
Platelets (mean (SD))  236.7 (55.5)  248.5  (54.5) 
  (n=97)  (n=76) 
Alkaline phosphatase (mean (SD))  60.0 (16.1)  64.7 (25.6) 
  (n=88)  (n=66) 
AST (mean (SD))  24.5 (12.9)  21.8 (6.8) 
  (n=89)  (n=66) 
ALT (mean (SD))  25.9 (19.8)  22.6 (10.9) 
  (n=89)  (n=66) 
Creatinine (mean (SD))  0.78 (0.25)  0.77 (0.33) 
  (n=102)  (n=79) 
Significant Proteinuria (n (%))  15/103† (14.6)  7/72† (8.9) 
Peripheral Nerve Involvement  (n (%))  51/51† (100)  41/42† (97.6) 
Characteristic Discovery Set Validation Set 
 Control (n=46) Patient (n=104) Control (n=34) Patient (n=79)  
Peripheral Nerve Severity (n (%))  n=51  n=41 
 1  8  (15.7)  5   (12.2) 
 2  20 (39.2)  20  (48.8) 
 3  10 (19.6)  7    (17.1) 
 4  7   (13.7)  3    (7.3) 
 5  6   (11.8)  6    (14.6) 
Cardiac Involvement (n (%))  28/51†  (54.9)  31/43† (72.1) 
Cardiac Severity (n (%))  n=28  n=31 
 Mild  10 (35.7)  13  (41.9) 
 Moderate  9   (32.1)  9    (29.0) 
 Severe  9  (32.1)  9    (29.0) 
Diabetes (n (%))  4/53† (7.6)   
†denominator is number with a yes or no answer to the question 
*t-test for continuous variables, chi-square for categorical variables 
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Patients are classified as symptomatic if they have constant and progressive symptoms as well as abnormal signs in the physical exam, particularly in the neurologic exam and abnormal 
laboratory exams that confirm cardiac and/or neuropathic involvement. The sensitivy of the biopsy is ≈ 80-90% A small subset of patients with negative amyloid biopsies were classified as 
asymptomatic with negative amyloid biopsies. 
We classified the severity of neuropathic involvement according to the commonly used 5-stage polyneuropathy disability score: stage 1 = sensory neuropathy without motor dysfunction; 
stage 2 = sensory and motor neuropathy, walking without assistance; 3 = sensory and motor neuropathy, patient needs unilateral support to walk; stage 4 = sensory and motor neuropathy, 
patient needs bilateral support to walk; stage 5 = patient is wheelchair bound or bedridden. 
There are two different types of cardiac involvement: patients may have myocardial infiltration with cardiomyopathy, alternatively they may present subendocardial infiltration with 
conduction disturbances, invariably leading to the utilization of a pacemaker. The first presentation is not common among Portuguese patients, the last is invariable present after a disease 
course of several years. We classified both types of cardiac involvement together and divided patients into three categories: 
Mild patients exhibit objective signs of cardiac involvement with abnormal EKG and/or abnormal proBNP and /or abnormal echocardiogram, but no symptoms. 
Moderate patients exhibit symptoms that interfere with physical exertion.  
Severe patients exhibit life-threatening conditions, such as conduction disturbances requiring a pacemaker or cardiomyopathy with symptoms of cardiac failure impairing regular daily 
activities. 
Table 2:  Demographic characteristics for all study patients and carriers. 
 Discovery Set of FAP Patients and asymptomatic carriers 
(n=104) 
 Validation Set of FAP Patients and 
asymptomatic carriers (n=79) 
 
Characteristic Asymptomatic (n=51) Symptomatic (n=53) p Asymptomatic (n=35) Symptomatic (n=44) p 
Sex—Female (n (%)) 27 (52.9) 28 (52.8)  18 (51.4) 23 (52.3)  
Age (years) (mean (SD)) 35.4 (11.9) 45.2 (14.8) .0003 31.1 (9.4) 44.0 (12.0) <.0001 
BMI (kg/m2) (mean (SD)) 25.5 (4.9) 23.5 (5.0) .05 24.4 (3.4) 24.3 (5.8) .90 
 (n=48) (n=49)  (n=35) (n=40)  
Parental Inheritance (n (%))   .27   .70 
 Mother 26 (51.0) 21  (39.6)  19  (45.7) 22  (50.0)  
 Father 24 (47.1) 24  (45.3)  16  (54.3) 17  (38.6)  
 Both 1  (2.0) 0   5    (11.4)  
 Unknown  8   (15.1)     
WBC (mean (SD)) 6.6 (1.7) 7.6 (2.0) .01 6.8 (2.0) 7.6 (2.4) .06 
 (n=48) (n=49)  (n=33) (n=44)  
Platelets (mean (SD)) 236.7 (49.7) 236.8 (61.2) .99 233.1 (48.9) 260.2  (56.2) .03 
 (n=48) (n=49)  (n=33) (n=43)  
Alkaline phosphatase (mean (SD)) 55.7 (16.5) 63.7 (14.9) .02 53.3 (13.0) 70.9 (28.5) .007 
 (n=41) (n=47)  (n=23) (n=43)  
AST (mean (SD)) 22.3 (8.7) 26.3 (15.6) .15 20.9 (6.5) 22.3 (6.9) .42 
 (n=41) (n=48)     
ALT (mean (SD)) 24.2 (14.8) 27.3 (23.3) .46 20.5 (9.3) 23.7 (11.6) .26 
 (n=41) (n=48)  (n=23) (n=43)  
  Note: one outlier with ALT = 159     
Creatinine (mean (SD)) 0.73 (0.16) 0.83 (0.32) .04 0.75 (0.13) 0.78 (0.42) .67 
 (n=51) (n=51)  (n=35) (n=44)  
Significant Proteinuria (n (%)) 1/51†  (2.0) 14/52†  (26.9) <.0001 0/35 (0) 7/44 (15.9) .01 
       
Peripheral Nerve Involvement  
(n (%)) 
1/1†  (100) 50/50†  (100)  0/1†  (0) 41/41† (100)  
Peripheral Nerve Severity (n (%))       
 1 1 (100) 7  (14)   5   (12.2)  
 2  20 (40)   20  (48.8)  
 3  10 (20)   7    (17.1)  
 4  7   (14)   3    (7.3)  
 5  6   (12)   6    (14.6)  
Cardiac Involvement (n (%)) 0/1† (0) 28/51† (56.0)  1/2†  (50.0) 30/41† (73.2)  
Cardiac Severity (n (%))  n=28  n=1 n=30  
 Mild  10 (35.7)   13  (43.3)  
 Moderate  9   (32.1)  1 (100) 8    (26.7)  
 Severe  9   (32.1)   9    (30.0)  
Diabetes (n (%)) 1/1† (100) 3/52†  (5.8)  0/0† 0/40†  (0)  
†denominator is number with a yes or no answer to the question. 
*t-test for continuous variables, chi-square for categorical variables. 
 
Discovery and validation of a molecular 
diagnostic in peripheral blood cells 
We first queried whether there is a gene 
expression signature that could distinguish 
asymptomatic V30M TTR carriers from symptomatic 
V30M FAP patients. To identify a robust and unbiased 
candidate diagnostic signature for all study subjects 
(both male and female) we split the 183 symptomatic 
V30M TTR FAP patients and asymptomatic V30M 
carriers into a Training and Test cohort (~85% of 
samples) and an external Validation cohort of samples 
(~15%). Both cohorts had equal representation of 
asymptomatic V30M TTR carriers and symptomatic 
V30M FAP subjects.  It is important to note that the 
external cohort of samples was “blinded” to the 
training and validation of the signature, which was 
done exclusively in the first cohort. In this way a true 
and unbiased estimate of the accuracy and the Area 
Under the Curve (AUC) of a “locked” classifier 
derived from the Training and Test cohort was 
possible. To further remove bias from a single 
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randomization, we randomized the 183-sample core 
dataset into 10 total randomizations and report the 
mean AUCs from all randomizations.  
For each randomization, a class comparison of 
symptomatic V30M TTR FAP patients and 
asymptomatic V30M carriers was performed in the 
Training and Test cohort using a False Discovery rate 
(FDR) of 5%. Signatures with feature (probeset) sizes 
of 30-200 were tested using the Support Vector 
Machines (SVM) algorithm for all randomizations 
with a 70 Training/30 Test split of the samples using 
bootstrapping with 100 iterations of the 
randomization experiments. The best performing 
models from the Training and Test for 10 
Randomizations were each “locked” and performance 
was tested on the External cohort of “blinded” 
samples. The Receiver Operating Characteristic 
(ROC) curves plotted on the 10 randomly selected 
external validation sets shown in Figure 1a had a 
mean AUC of 0.81 ± 0.05. The diagnostic metrics for 
all 10 randomizations are shown in Table 3.  
Another rigorous method to test whether the 
obtained classifier is subject to statistical over-fitting 
(this would inflate the claimed predictive results) can 
be done with the method of Harrell et al. [37]. This 
method uses bootstrapping to get bias-corrected 
(overfitting corrected) estimates of predicted vs. 
observed values of diagnostic accuracy using a 
logistic regression model.  This is accomplished by 
sampling with replacement, where the sample labels 
are randomly reassigned for 500 bootstrap iterations. 
Using this method we ran classifier models with 
features (genes) ranging from 20–70 genes, chosen 
from the differential expression analysis of all 
asymptomatic vs. symptomatic FAP subjects ranked 
by p-values. All models were tested for 500 bootstrap 
iterations in the regression modeling strategies (rms) 
R package [34]. We then created a plot of the “bias 
corrected” AUCs for models using the different 
feature sizes (20-70) as shown in Figure 1b. The 
results show that the classifier models tested had a 
range of AUCs from 0.74 to 0.87 using 20-70 genes. 
The optimal results (AUCs >0.80) were obtained with 
gene sets greater than 50, consistent with the 
importance of using a larger number of genes for a 
robust classifier to accurately distinguish 
symptomatic and asymptomatic FAP subjects.  
Table 3. The diagnostic metrics of the SVM classifiers for all 10 randomizations of the symptomatic vs. asymptomatic subjects in the study. 
Diagnostic Metric Mean Range SD Lower CI Upper CI 
Sensitivity (TP/(TP+FN)) 0.844 0.169 0.065 0.798 0.891 
Specificity (TN/(FP+TN)) 0.805 0.308 0.139 0.731 0.933 
Positive Predictive Value (TP/(TP+FP)) 0.829 0.312 0.126 0.739 0.919 
Negative Predictive Value (TN/(FN+TN)) 0.825 0.173 0.069 0.782 0.886 
Matthews Correlation Coefficient  ((TP*TN-FP*FN)sqrt(P*N*P’*N’)) 0.652 0.406 0.127 0.561 0.743 
Area Under Curve (((TP/(TP+FN))+ (TN/(FP+TN))*0.5) 0.819 0.192 0.057 0.778 0.859 
Likelihood Ratio 8.920 12.340 3.550 6.381 11.468 
CI=Confidence Interval. 
 
       
Figure 1: Class comparison of symptomatic V30M TTR FAP patients and asymptomatic V30M carriers. (a) ROC curves for 10 randomly selected external validation data sets 
derived from signatures with feature (probeset) sizes of 30-200 using the Support Vector Machines (SVM) algorithm with a 70 Training/30 Test split of the samples and 
bootstrapping with 100 iterations. The best performing models from the Training and Test cohorts for 10 Randomizations were each “locked” and performance was tested on 
the External cohort of “blinded” samples. (b) Bias-corrected plot of the AUCs for sex-independent classifiers of different feature sizes (20-70) using a logistic regression model. 
The classifier models tested had a range of AUCs from 0.74 to 0.87 using 20-70 genes. The optimal results (AUCs >0.80) were obtained with gene sets greater than 50.  
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Figure 2: Class comparison of female symptomatic V30M TTR FAP patients and asymptomatic V30M carriers. (a) ROC curve for symptomatic vs. asymptomatic FAP female 
subjects using an SVM “locked” best model comprised of 80 genes and 500 bootstrap iterations with sensitivity, specificity, PPV and NPV of 76%, 80%, 81% and 75%, respectively. 
(b) The Harrell bootstrapping plot of the “bias-corrected” AUCs for female specific classifiers of different feature sizes (20-70) using a logistic regression model. The results again 
show that models with >50 genes/features give AUCs >80%. 
 
Evidence for sex-specific signatures in 
symptomatic vs. asymptomatic carriers 
The second question addressed was whether 
there are gender-specific genomic signatures that can 
differentiate symptomatic male and female V30M 
FAP patients from asymptomatic V30M TTR carriers. 
This inquiry was motivated by the fact that male 
V30M FAP patients have earlier onset and more 
aggressive disease progression than female V30M 
FAP patients. This is particularly true for males that 
inherit the mutant gene from their mothers. The same 
tools and comparisons as described above for the sex 
independent signature were applied to the males and 
females as separate cohorts The only exception was 
that due to the smaller sample sizes (females; n = 96 
and males; n = 87) only one random internal 70% 
Training and 30% Test data split was performed with 
500 iterations by bootstrapping. The purpose of this 
work was to establish a proof-of-concept for 
sex-specific signatures. Independent data set 
validations of these signatures will be required before 
any claims of a diagnostic are considered.  
In the females, there were 125 genes that were 
differentially expressed between the symptomatic and 
asymptomatic subjects. A SVM “locked” best model 
comprising 80 genes and 500 bootstrap iterations gave 
an AUC of 0.7874 (Figure 2a) with a sensitivity, 
specificity, Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV) of 76%, 80%, 81% 
and 75%, respectively. The Harrell bootstrapping plot 
of the “bias corrected” AUCs for models using 
different feature sizes (20-70) using a logistic 
regression model in the females is shown in Figure 
2b. The results again show that models with >50 
genes/features give AUCs >80%.  
When the same comparisons were made with the 
male symptomatic V30M FAP and asymptomatic 
V30M TTR carriers, there were 353 differentially 
expressed genes between symptomatic and 
asymptomatic males. We tested classifier models 
using 20-200 of the differentially expressed genes 
ranked by p-value.  The SVM best model best-fit 
classifier comprised all 200 genes. This classifier had 
an AUC of 0.8268 and sensitivity, specificity, PPV and 
NPV of 80%, 82%, 84% and 79%, respectively (Figure 
3a). The Harrell bootstrapping plot of the “bias 
corrected” AUCs for models using different feature 
sizes (20-70) is shown in Figure 3b. The male 
signatures achieved AUCs >80% when more than 50 
genes were used.  
Developing molecular scores and evaluating 
tafamidis-treated samples 
A simple classifier validated for differentiating 
between symptomatic V30M FAP patients vs. 
asymptomatic V30M carriers does not reflect disease 
severity or change in response to therapy. Serial 
monitoring requires translation of the classifier’s 
output to a continuous variable or molecular score 
based on the underlying gene expression derived 
from the classifier. Therefore, we developed a method 
for calculating molecular scores (see Supplemental 
Methods). A desirable future study would be to allow 
clinicians to serially monitor disease progression, and 
response to therapy. 
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Figure 3: Class comparison of male symptomatic V30M TTR FAP patients and asymptomatic V30M carriers. (a) ROC curve for the SVM best model best-fit classifier for 
symptomatic vs. asymptomatic FAP male patients. This classifier comprised 200 genes had an AUC of 0.8268 and sensitivity, specificity, PPV and NPV of 80%, 82%, 84% and 79%, 
respectively. (b) The Harrell bootstrapping plot of the “bias-corrected” AUCs for male specific classifiers of different feature sizes (20-70) using a logistic regression model. The 
male signatures achieved AUCs >80% when more than 50 genes were used.  
 
First, the molecular scores were calculated for 
symptomatic FAP vs. asymptomatic V30M carriers 
and analyzed as a single cohort, independent of sex. 
Since we had tested signatures using 10 different 
randomizations for the sex-independent molecular 
diagnostic, we chose a core set of 96 genes that were 
common to all 10 randomizations to calculate the 
molecular scores. As shown in Figure 4a, it is clear 
from the discovery set that the symptomatic patients 
had significantly higher molecular scores than both 
the asymptomatic V30M carriers (p=7.2E-13) and 
healthy controls (0.0001). Interestingly, the molecular 
scores of the asymptomatic FAP carriers are 
significantly lower than the healthy controls (7.1E-05).  
Scores were then generated for the 46 
tafamidis-treated FAP patients as another kind of 
validation. The scores for symptomatic FAP patients 
after 3 months of tafamidis therapy showed 
significant improvement (p=0.003), dropping to levels 
roughly comparable to the healthy controls (p=0.29; 
NS) but still significantly higher than asymptomatic 
FAP subjects (p=0.0002). These results were obtained 
after only 3 months of tafamidis treatment (20 mg 
once daily) of symptomatic FAP patients.  
We also calculated the molecular scores for 
female and male-specific signatures. The molecular 
scores clearly separated the female symptomatic and 
asymptomatic V30M carriers (p=2.2E-07) and the 
healthy controls (p=0.001) (Figure 4b). The scores also 
effectively separated the symptomatic and 
tafamidis-treated female patients (p=2.4E-05). We 
confirmed the score’s female specificity by calculating 
the scores for these female-specific genes in the males 
and the result was not significant (p=0.16).  Similarly, 
the male-specific molecular scores demonstrated clear 
separations between male symptomatic patients and 
asymptomatic V30M carriers (p=2.3E-09; Figure 4c) as 
well as healthy male controls (p=0.001). There were 
also significant differences in the scores between the 
tafamidis-treated males and the symptomatic males 
(p=0.03), consistent with a response to therapy, 
although the scores did not normalize to the level of 
asymptomatic V30M male carriers.  
Mapping the biology of gender-independent 
and gender-specific genes  
One value of using global gene expression 
profiling is the ability to use bioinformatic tools to 
map the expression of differentially expressed genes 
to known biological functions. The key is to correlate 
this mapping with the clinical phenotypes. First, a 
p-value cut-off of <0.005 and an FDR of <3% was set 
for comparing all symptomatic FAP to asymptomatic 
V30M carriers. There were 1534 significantly 
differentially expressed probesets representing 1426 
annotated genes. These genes were associated with 36 
significant pathways (Benjamini-Hochberg corrected 
p-value <0.05) (Table S1). 285 genes (18%) mapped to 
immune/inflammatory processes. There was a 
marked down-regulation of pathways such as eIF2, 
primary immunodeficiency signaling, and purine 
nucleotide biosynthesis in symptomatic patients, 
whereas signaling networks for FCγ, TREM1, NK 
cells, and cytokines IL3, IL15, and IL22 were 
upregulated.  
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An analysis of upstream regulators was done to 
identify genes that are putative drivers of the 
downstream expression changes. This analysis 
identified a set of 23 candidate driver genes, with 11 
of the 23 (48%) being known transcriptional 
regulators (Table S2). Two powerful candidate 
drivers based on upstream activation scores were 
IFNG and FOXO1 that mapped to the expression of 38 
target molecules known in the literature to be 
upregulated by IFNG and 10 known to be 
downregulated by FOXO1 (Figures 5a & b and Table 
S2). 
To map the biology of the male- and 
female-specific genes, class comparisons were made 
between the asymptomatic and symptomatic males 
and females separately. At p<0.005 there were 588 
differentially expressed genes in the females 
(FDR<10%; Table S3) and 894 differently expressed 
genes in the males (FDR<6%; Table S4). Only 49 
genes (3%) were shared between the male and female 
signatures, confirming that male and female FAP 
patients have very specific and different patterns of 
gene expression. Of the 588 differentially expressed 
genes in the females, there were only 66 molecules 
associated with immune/inflammation processes, 
and of these, only 11 (17%) were upregulated in the 
symptomatic females as compared to the 
asymptomatic females. The majority of all genes (438 
genes; 75%) were downregulated in symptomatic 
females. In contrast to the females, 691 (78%) of the 
894 differentially expressed genes in the symptomatic 
males were upregulated and 179 were associated with 
immune/inflammatory processes. Of the latter, 146 
(82%) were upregulated.  
     
 
 
Figure 4: Box plots of the molecular scores. (a) Molecular scores calculated for symptomatic FAP vs. asymptomatic V30M carriers with a core set of 96 genes common to all 
10 randomizations, used to generate the sex-independent molecular diagnostic. The symptomatic patients had significantly higher molecular scores than both the asymptomatic 
V30M carriers (p=7.2E-13) and healthy controls (p=0.0001). The molecular scores of the asymptomatic FAP carriers are significantly lower than the healthy controls (p=7.1E-05). 
Tafamidis treatment of the symptomatic patients significantly (p=0.003) lowered the molecular scores. (b) Molecular scores for female-specific signatures which clearly separated 
the female symptomatic and asymptomatic V30M carriers (p=2.2E-07) and the healthy controls (p=0.001). The scores also significantly separated the female symptomatic and 
tafamidis-treated female patients (p=2.4E-05). (c) Molecular scores for male-specific signatures which clearly separated the male symptomatic and asymptomatic V30M carriers 
(p=2.3E-09). The scores also separated the male symptomatic and tafamidis-treated male patients (p=0.03). 
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Figure 5: Expression of two candidate driver genes and their target genes. IFNG and FOXO1 are the two most powerful genes (by activation scores) that were identified by an 
analysis of upstream regulators known to be putative drivers of downstream expression changes. (a) 38 target molecules known in the literature to be upregulated by IFNG, and 
(b) 10 molecules known to be downregulated by FOXO1. 
 
In the females, there were only 4 significant 
canonical signaling pathways: eIF2, primary 
immunodeficiency, T-helper cell differentiation, and 
iCOS signaling (Table S5). Strikingly, almost all the 
genes that were associated with these pathways were 
downregulated in symptomatic females. In the males, 
there were 29 significant canonical pathways linked to 
immunity such as Fcγ receptor, natural killer cell, 
Toll-like receptor, B Cell receptor, leukocyte 
extravasation, and IL-12 Signaling (Table S5).  As 
noted previously, the majority of genes associated 
with these pathways were upregulated in 
symptomatic males. 
In summary, the symptomatic males reveal 
upregulated inflammation-associated genes and 
pathways (Figure 6a). The male-specific inflammatory 
genes are not differentially expressed in symptomatic 
females (Figure 6b).  
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Figure 6: Expression of the male-specific inflammatory genes in FAP subjects. (a) Symptomatic males reveal upregulated inflammation-associated genes and pathways.  (b) 
Male-specific inflammatory genes are not differentially expressed in symptomatic females. 
 Theranostics 2016, Vol. 6, Issue 11 
 
http://www.thno.org 
1803 
In contrast, there is a marked downregulation of 
the eIF2α signaling pathway in symptomatic females 
(Figure 7a), and that difference is not seen in males, 
who actually show upregulated expression of some 
proximal signaling molecules (Figure 7b). The eIF2 
pathway is also globally downregulated in all 
symptomatic patients compared to asymptomatic 
V30M carriers (Figure 7c). Finally, it is important to 
emphasize that the genes identified by analysis of all 
the patients as differentially expressed and 
independent of sex reveals another set of potential 
mechanistic pathways for FAP disease that should be 
simply added to the candidates revealed by 
sex-specific analysis (Tables S1 and S2; Figure 5a and 
5b).  
Because there was a correlation of upregulated 
immune/inflammatory genes in symptomatic FAP 
males but not symptomatic females, we analyzed the 
146 male-specific immune/inflammatory genes and 
determined their expression in the females by 
molecular scores (Figure 8). Indeed, the basal level of 
gene expression for these male-specific inflammatory 
genes was relatively high in all women including the 
healthy female controls. 
Among the 894 differentially expressed genes in 
the males, 47 proteins are targets of 95 known drugs 
(Table S5). These included tocilizumab, a humanized 
monoclonal antibody against the interleukin-6 
receptor (IL-6R); anakinra, an interleukin-1 (IL-1) 
receptor antagonist that blocks the biologic activity of 
naturally occurring IL-1; talmapimod, a selective 
inhibitor of p38 mitogen-activated protein kinase 
(MAPK), a potential agent with immunomodulating, 
anti-inflammatory and antineoplastic activities. 
Another interesting drug was lexipafant (BB-882), a 
platelet activating factor receptor antagonist, which 
has been identified as an agent that may reduce the 
severity of the inflammatory responses to liver injury 
in animal models.   
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Figure 7: Expression of eIF2α signaling pathway genes. (a) There is a marked downregulation of the eIF2α signaling pathway in symptomatic females. (b) Similar differences are 
not seen in males, who actually show upregulated expression of some proximal signaling molecules. (c) The eIF2 pathway is also globally downregulated in all symptomatic 
patients compared to asymptomatic patients. 
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Figure 8: Box-plots of the molecular scores of the 146 male-specific immune/inflammatory genes. Expression of the immune/inflammatory genes differentially upregulated in 
symptomatic males was scored in female FAP subjects and healthy controls and in male FAP subjects and healthy controls.  The basal level of gene expression for these 
male-specific inflammatory genes was relatively high in all women including the healthy female controls. 
 
Multi-analyte plasma protein panel for 
inflammatory genes 
A commercial plasma proteomic panel for 
inflammatory molecules was used to profile 44 
different analytes in plasma samples from 40 selected 
V30M carriers, comprised of equal numbers of male 
and female subjects, and equal numbers of 
symptomatic FAP and asymptomatic subjects (Table 
S6). 31 analytes were consistently detected in the 
plasma above threshold. There were 5 
inflammation-linked plasma proteins that were 
significantly differentially upregulated among the 
symptomatic males (p<0.05): Alpha-2-Macroglobulin, 
Ferritin, Tissue Inhibitor of Metalloproteinases-1 
(TIMP1) and Vascular Cell Adhesion Molecule-1. 
Interleukin-7 (IL7) was significantly downregulated 
in symptomatic males. IL7 is an important growth 
factor for T and B cells produced through TLR4 
signaling by the liver, dendritic, stromal and intestinal 
epithelial cells and low expression has been linked in 
mouse models to pathogenesis of Experimental 
Autoimmune Encephalitis [38]. Among the 
symptomatic females, 4 proteins were significantly 
upregulated (p<0.05): Macrophage Inflammatory 
Protein-1 beta (MIP1b), Monocyte Chemotactic 
Protein-1 (MCP1), Complement C3 and Beta 2 
Microglobulin. Analysis of the males and females 
together found 6 significantly upregulated 
inflammatory markers in the plasma: eotaxin 1, 
ferritin, TIMP1, MIP1b, and MCP1.  
Discussion 
Using global gene expression profiling of 
peripheral blood cells from two independent cohorts 
of asymptomatic V30M carriers, symptomatic V30M 
FAP patients and age- and sex-matched local healthy 
controls, we identified three different signatures: a 
signature for differentiating symptomatic vs. 
asymptomatic FAP male subjects, a different 
signature for distinguishing symptomatic vs. 
asymptomatic FAP female subjects, and a third 
sex-independent signature for differentiating 
symptomatic vs. asymptomatic FAP. The latter 
signature as a continuous variable or molecular score 
showed a reduction in response to tafamidis 
treatment in a third completely independent cohort of 
symptomatic FAP patients, demonstrating the 
robustness of our classifier and scoring methodology.  
There have been very few studies that look at the 
global expression of genes that might drive 
post-mitotic tissue loss in FAP patients. One 
microarray study in clinical FAP looked at salivary 
glands of 4 symptomatic patients [39]. Only two genes 
were identified as differentially expressed and 
validated using qPCR; biglycan and neutrophil 
gelatinase-associated lipocalin (NGAL). In our gene 
expression profiling, NGAL (LCN2) mRNA levels did 
not differ between symptomatic and asymptomatic 
patients, despite being moderately expressed (raw 
signals ~200 across all samples studied). We did not 
measure NGAL protein levels in this study. Another 
gene profiling study in symptomatic V30M Swedish 
TTR amyloidosis patients was done with biopsies of 
adipose tissue (n=12) and liver (n=9) vs. normal 
healthy controls (n=16) [40]. While there were no 
significant differences found in adipose tissue 
biopsies (TTR target tissue), evidence for an impaired 
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ER/protein folding pathway in the livers was 
revealed.  
A recent study investigated the biological effects 
of TTR proteins on angiogenesis using primary 
human umbilical vein endothelial cells (HUVECs; 
n=6) exposed to the WT or V30M TTR tetramer [41]. 
Exposure to the V30M tetramer down-regulated 
many pro-angiogenic genes such as VEGFR1, 
VEGFR2, FGF2, TGFB2, and ANGPT2 and also 
inhibited migration and decreased HUVEC survival 
by inducing apoptosis. Consistent with these results, 
we demonstrated differential expression of the VEGF 
and FGF pathways in the symptomatic patients 
(p=0.025 and 0.03, respectively).  
The results presented above corroborate our 
recent study of a murine model of wild type human 
TTR cardiac amyloidosis. Microarray analysis of the 
TTR synthesizing tissue (liver) and a target of TTR 
deposition (heart) revealed substantial transcriptional 
evidence of inflammation in the target tissue prior to 
the time of deposition, which diminished (relative to 
mice without deposits) after deposition.  There was 
also transcriptional evidence in the hearts consistent 
with hypoxia and possible heart failure, including 
expression of VEGF and genes downstream in the 
VEGF pathway and evidence of B cell and immune 
activation via T cell receptor pathways [42].  
There is limited evidence demonstrating a link 
between FAP and inflammation. Chronic 
administration of an IL-1 antagonist (Anakinra) that 
alleviates inflammation in mice that deposit TTR, but 
do not exhibit FAP phenotypes, reveal that Anakinra 
prevents extracellular deposition of TTR in the sciatic 
nerve and inhibits apoptosis [43]. In a separate study, 
altering the threshold of the inflammatory response in 
injured mice reveal that Anakinra differentially 
regulates TTR expression and deposition [44]. 
Amyloid fibrils have been shown to bind and signal 
through the cell surface Receptor for Advance 
Glycation End-products (RAGE), to upregulate NFkB 
that is linked to a number of cell stress and 
inflammatory pathways including IL6 and TNF [45]. 
Immunohistochemical analysis of nerve biopsies from 
16 symptomatic FAP patients showed upregulated 
expression of RAGE, IL1b, TNF, and iNOS [46]. 
Interestingly, diflunisal, a generic nonsteroidal 
anti-inflammatory drug has been successfully 
repurposed for the treatment of FAP. In a global, 
multicenter clinical trial of 130 patients with FAP, 
diflunisal treatment reduced the rate of progression of 
neurological impairment [20]. Diflunisal was assessed 
in the clinical trial not because of its potential 
anti-inflammatory properties, but rather because 
diflunisal, like tafamidis, binds to TTR, kinetically 
stabilizing the circulating TTR tetramers and thereby 
inhibiting the release of the TTR monomer required 
for amyloidogenesis [47, 48]. It is tempting to 
hypothesize that some of the alleviation of FAP 
symptoms might be due to the anti-inflammatory 
effect of diflunisal, though metrics for inflammation 
were not measured. It would be interesting to 
compare the transcriptional profiles of patients 
treated with diflunisal to those of patients treated 
with tafamidis, which has no known 
anti-inflammatory properties, to look for similar (or 
potentially different) mechanisms. In such an 
envisioned clinical trial comparison, it is imperative 
that the doses of tafamidis and diflunisal be adjusted 
so that they kinetically stabilize transthyretin equally. 
This has not been done in the trials carried out to date. 
Sex-specific differences in immune and 
inflammatory responses are believed to be responsible 
for differences in the risks for various disease states, 
such as increased cardiovascular disease in males [49, 
50] and increased risk for autoimmune disease in 
females [51, 52]. This is also true in the response to 
bacterial infections, which is impaired in males 
relative to females [53, 54]. Basal cell surface 
expression levels of the LPS-binding Toll-like 
receptor-4 (TLR4) and its co-receptor CD14 are higher 
in macrophages of males relative to females [55]. In 
our data both TLR4 and CD14 were differentially 
upregulated in symptomatic males compared to 
asymptomatic males, and neither was differentially 
expressed in females. Other TLRs such as TLR2, TLR6 
and TLR8 also showed a male-specific upregulation in 
our study.  
The correlation of upregulated immune/ 
inflammatory genes in symptomatic FAP males, but 
not in symptomatic females, suggests different roles 
for immune/inflammatory pathways in men vs. 
women. Notably, the absence of upregulation in 
females should not be interpreted as inflammation 
being absent in females. Indeed, the basal level of 
gene expression for the male-specific inflammatory 
genes was relatively high in all women regardless 
whether they were symptomatic, asymptomatic or 
healthy controls. Thus, it is possible that certain 
pathways of inflammation may be a factor in 
symptomatic FAP in both sexes but since females 
have higher baseline levels of expression of these 
inflammatory genes, there is no significant differential 
change when symptomatic vs. asymptomatic subjects 
are compared. It is also possible that inflammation is 
better tolerated by females. Thus, inflammation may 
be triggered in both symptomatic and asymptomatic 
females and not be the only mechanism driving the 
conversion to a symptomatic state in females.   
The most differentially expressed pathway, the 
eIF2 pathway, was downregulated in all V30M FAP 
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patients relative to asymptomatic carriers. Multiple 
signaling pathways drive the integrated stress 
response pathways that phosphorylate eIF2, slowing 
the rate of translational initiation. The eIF2 kinase, 
PERK, senses accumulation of misfolded or 
aggregated proteins in the lumen of the endoplasmic 
reticulum where TTR is biosynthesized [56-58]. 
Activation of the PERK arm of the unfolded protein 
response reduces global protein synthesis and 
remediates the overloaded endoplasmic reticulum 
secretory pathway via eIF2 phosphorylation. 
Downregulation of the eIF2 family of transcripts is 
seen irrespective of gender and could be the major 
mechanism involved in the females in the lack of a 
differential expression of inflammatory signals. In the 
symptomatic subjects, the eIF2 pathway showed 
33/38 differentially expressed molecules as being 
downregulated, including a host of ribosomal 
proteins.  
Surprisingly, we show that the molecular scores 
for asymptomatic FAP carriers are lower than healthy 
controls for all groups evaluated, but this is not 
unprecedented. Down-regulation of host defense 
response genes and selective up-regulation of genes 
associated with protection in the peripheral blood of 
asymptomatic dengue patients was shown using 
microarrays [59]. Another study showed that high 
levels of migration inhibitory factor (MIF), a cytokine 
implicated in the pathogenesis of a number of human 
inflammatory diseases, were found in the peripheral 
blood of cerebral malaria patients and may be 
associated with fatal outcomes. MIF protein levels, as 
measured by ELISA, were lower in patients with a 
mild form of malaria than even healthy controls [60]. 
This inverse correlation between protection and MIF 
levels was observed previously, where significantly 
reduced circulating MIF levels were seen in children 
with acute malaria infection compared to matched 
healthy controls [61]. 
A common question for any molecular 
diagnostic is how specifically it can diagnose the 
disease of interest relative to maladies with similar 
clinical phenotypes. In the case of FAP, patients 
harbor a genetic mutation, which along with an 
amyloid positive biopsy and abnormal physical and 
laboratory exams constitutes a definitive FAP 
diagnosis (see Table 1 legend). We envision that the 
peripheral blood cell FAP signature could become a 
complementary diagnostic strategy, however we 
recognize that the prevalence of V30M FAP in the 
Portuguese population is high (0.001% in the endemic 
areas). The clinical presentation and the age of onset 
are more variable in the Swedish and Japanese 
populations [30, 62, 63]. We acknowledge that the 
prevalence of FAP in the Portuguese population 
studied could influence the PPV and NPV of the test. 
However, we envision that our diagnostic signature 
would initially be validated in other FAP populations 
where the prevalence is also high, such as the 
Japanese and Swedish populations of allele carriers. 
Whether the signatures identified will be specific for 
FAP in populations with lower disease prevalence 
and higher genetic diversity like the US population 
remains to be established. 
We also acknowledge that we need to study 
other related peripheral neuropathies to test the 
specificity of expression profile as an early diagnostic 
strategy. The fact that some of the major pathways 
identified by our signatures are related to 
immune/inflammatory activation gives us confidence 
that our signatures are probably not similar to 
idiopathic polyneuropathy, but that will need to be 
tested.  
Another question is how such a potential 
molecular diagnostic would be used in clinical 
practice. We envision that once V30M carriers are 
identified, serial monitoring of the molecular scores 
could give clinicians early warning of increasing risk 
for developing symptomatic FAP, at which point 
these patients could be brought back to the clinic for 
amyloid biopsy. There is compelling data already 
available that the earlier treatment is started, the 
better the outcome [17-22]. Whether the molecular 
scores will correlate well enough with response to 
therapy to guide individualized dosing decisions will 
require a prospective, properly powered clinical 
study that includes serial observations of patients 
over time. It is also possible that these molecular 
scores will be considered in parallel with Technetium 
Pyrophosphate Scanning [64-66] and magnetic 
resonance imaging [67] for diagnosing symptomatic 
transthyretin aggregation-associated cardiomyopathy 
and polyneuropathy, respectively. 
In conclusion, our data from the peripheral 
blood cells of FAP patients reveal a first generation 
sex-independent diagnostic molecular signature for 
symptomatic FAP that correlates with response to 
tafamidis therapy. Equally importantly, this data 
generates several testable hypotheses about putative 
driver and compensatory mechanisms in FAP that 
will require further study. We also demonstrate that 
there are sex-specific FAP signatures that are different 
than the sex-independent profiles. While these 
sex-dependent differences will need further 
validation in independent cohorts in the next stage of 
work, they offer the potential to explain why male 
patients generally progress faster in FAP. The trend 
toward normalization of the scores of all groups of 
FAP patients treated with tafamidis motivate longer 
prospective studies to determine whether this 
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strategy of blood gene expression profiling could 
become a useful biomarker for response to treatment. 
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